Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037971 | 0.99 | OPRL1 (0.40) | OPRL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24038006 | 0.97 | OPRL1 (0.39) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25533481 | 0.92 | OPRL1 (0.38) | OPRL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24037983 | 0.90 | OPRL1 (0.39) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24037651 | 0.90 | OPRL1 (0.37) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24038011 | 0.87 | OPRL1 (0.39) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL26067120 | 0.86 | OPRL1 (0.41) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23718564 | 0.85 | OPRL1 (0.40) | OPRL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23680209 | 0.85 | OPRL1 (0.38) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23718792 | 0.85 | OPRL1 (0.38) | OPRL1AKT1OPRD1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | CFD, DDOST, HEXD | OPRL1 2635/4885HDAC3 2474/4885HDAC4 2531/4885 |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | GLP1R, ADGRF1, CCKAR | OPRL1 269/4885HDAC3 2038/4885HDAC4 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.